Authors: Paganelli, G Zoboli, S Cremonesi, M Bodei, L Ferrari, M Grana, C Bartolomei, M Orsi, F De Cicco, C Maacke, HR Chinol, M de Braud, F

Citation: G. Paganelli et al., Receptor-mediated radiotherapy with Y-90-DOTA-D-Phe(1)-Tyr(3)-octreotide, EUR J NUCL, 28(4), 2001, pp. 426-434

Authors: Paganelli, G Zoboli, S Cremonesi, M Macke, HR Chinol, M

Citation: G. Paganelli et al., Receptor-mediated radionuclide therapy with Y-90-DOTA-D-Phe(1)-Tyr(3)-octreotide: Preliminary report in cancer patients, CANC BIO R, 14(6), 1999, pp. 477-483

Authors: Cremonesi, M Ferrari, M Zoboli, S Chinol, M Stabin, MG Orsi, F Maecke, HR Jermann, E Robertson, C Fiorenza, M Tosi, G Paganelli, G

Citation: M. Cremonesi et al., Biokinetics and dosimetry in patients administered with In-111-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with Y-90-DOTATOC, EUR J NUCL, 26(8), 1999, pp. 877-886

Authors: Paganelli, G Grana, C Chinol, M Cremonesi, M De Cicco, C De Braud, F Robertson, C Zurrida, S Casadio, C Zoboli, S Siccardi, AG Veronesi, U

Citation: G. Paganelli et al., Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin, EUR J NUCL, 26(4), 1999, pp. 348-357

Authors: Bartolomei, M Testori, A Chinol, M Gennari, R De Cicco, C Leonardi, L Zoboli, S Paganelli, G

Citation: M. Bartolomei et al., Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping, EUR J NUCL, 25(11), 1998, pp. 1489-1494